EDAP Appoints Medical Director; Enhanced Marketing and Clinical Team Positioned for HIFU Success and High Growth
07 December 2005 - 6:28AM
PR Newswire (US)
LYON, France, Dec. 6 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), the world leader in High Intensity Focused
Ultrasound treatment of localized prostate cancer, is pleased to
announce the appointment of Dr. Raphael Varona as Medical Director.
Dr. Varona will assist physicians in using the Ablatherm(R)-HIFU,
particularly in the early stages, and will enhance market
education. He will work to advance reimbursement efforts for HIFU
therapy with authorities in European countries where reimbursement
is still pending. Dr. Varona will expand the already significant
body of HIFU clinical data while adding to clinical credibility and
support from EDAP's key opinion leaders and will help enhance the
clinical benefits provided to the patients with Ablatherm(R)-HIFU
compared to established treatment modalities. He will be the
reporting person for follow-up on FDA clinical trial progress,
together with EDAP's U.S. partner HealthTronics. Finally, while
assisting in positioning the Ablatherm-HIFU treatment, Dr. Varona
will also work on developing additional HIFU applications. Dr.
Varona is a medical doctor specializing in Public Health and
Epidemiology. He has worked in the international pharmaceutical
industry since 1990 with responsibilities in clinical development,
project management and medical support for marketing in multiple
therapeutic areas. Throughout his career, Dr. Varona has
accumulated strong experience in urology and especially in
oncology. Dr. Varona served as European Clinical Project Manager
for Dupont Pharma (a subsidiary of Dupont de Nemours) prior to
acquisition by Bristol- Myers Squibb Corp. and recently worked for
UCB Pharma, a multinational company, as a clinical research
physician. He has substantial experience in successfully bringing
new medical products to market, coordinating multicentric studies,
and developing clinical and marketing strategy. He obtained a
Medical degree from the University of Zaragoza, Spain, and
specialized in Public Health, from University of Nancy, France. Dr.
Varona is fluent in English, Spanish and French. "I am impressed by
the compelling clinical outcomes of Ablatherm-HIFU and the rapidly
growing number of centers promoting the therapy worldwide. EDAP is
clearly the market leader as indicated by its reputation in the
medical community with Ablatherm-HIFU positioned as the alternative
for localized prostate cancer treatment even in some of the most
difficult cases. I am convinced Ablatherm-HIFU is positioned to
grow rapidly in existing markets as well as continue to expand its
worldwide presence by continuing to demonstrate its value to local
medical communities. I am very excited by the benefits that HIFU
therapeutic principles bring to the patient and look forward to
expanding its potential indications for prostate cancer and
beyond," said Dr. Varona. Hugues de Bantel, EDAP's Chief Executive
Officer, commented, "With a stronger-than-ever management team and
our confirmed leadership position in clinical credibility on HIFU
for prostate cancer, we are clearly heading for high growth. As we
committed to our shareholders earlier this year, we have
strengthened our marketing and clinical team and are ready to drive
an international marketing campaign to educate doctors, patients
and reimbursement providers and accelerate our sales capabilities.
To do so, Dr. Varona will be working closely with Fabrice Romano,
our Marketing Director. Together, they will champion our cause to
increase public awareness and accelerate market acceptance of HIFU
as a preferred treatment for prostate cancer. We look forward to
reporting to our shareholders very soon about EDAP's current
exciting progress in new installations and cost-per-procedure
business growth." About EDAP TMS S.A. EDAP TMS S.A. develops and
markets Ablatherm, the most advanced and clinically proven choice
for High Intensity Focused Ultrasound (HIFU) treatment of localized
prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side
effects. The company is also developing this technology for the
treatment of certain other types of tumors. EDAP TMS S.A. also
produces and commercializes medical equipment for treatment of
urinary tract stones using Extra-corporeal Shockwave Lithotripsy
(ESWL). For more information on the Company, contact the Investor
Relations Dept by phone at +33 (0)4 78 26 40 46 or see the
Company's Web site at: http://www.edap-tms.com/ . This press
release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described
in the Company's filings with the Securities and Exchange
Commission. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe
Chauveau Blandine Confort +33 4 78 26 40 46 Halliburton Investor
Relations Matt Kreps - Geralyn DeBusk 972 458 8000 DATASOURCE: EDAP
TMS S.A. CONTACT: Hugues de Bantel, Philippe Chauveau or Blandine
Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or
Geralyn DeBusk, both of Halliburton Investor Relations,
+1-972-458-8000, for EDAP TMS S.A. Web site:
http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024